PHAT

Phathom Pharmaceuticals
PHAT

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$298.13M
EV
$555.81M
Shares Outstanding
68.38M
Beta
0.35

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$20.88
P/E 2025E
-
P/Revenue 2025E
1.82x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Phathom Pharmaceuticals, Inc.

gainify
PHAT

Phathom Pharmaceuticals, Inc.

PHAT

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker ...

Sector

Healthcare

Industry

Biotechnology

CEO

Curran, Terrie

Employees

427

IPO Date

2019-10-25

Headquarters

100 Campus Drive, Suite 102, Florham Park, New Jersey, 07932, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved